Stock Scorecard



Stock Summary for Innoviva Inc (INVA) - $18.97 as of 5/27/2025 3:11:59 PM EST

Total Score

9 out of 30

Safety Score

38 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for INVA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for INVA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for INVA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for INVA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for INVA (38 out of 100)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 7
Book Value (Max of 10) 5
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for INVA

Basilea announces commercial availability of antibiotic Zevtera® ( ceftobiprole ) in the United States 5/20/2025 5:15:00 AM
Rep. George Whitesides Has Sold Up to $5.18M Worth Of Innoviva Stock: Here's What You Should Know - Innoviva ( NASDAQ:INVA ) 4/24/2025 3:00:00 PM
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - American Axle & Mfg Hldgs ( NYSE:AXL ) , Alumis ( NASDAQ:ALMS ) 4/1/2025 11:56:00 AM
Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow 2/18/2025 6:15:00 AM
Basilea provides portfolio update and outlook 1/8/2025 6:15:00 AM
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® ( ceftobiprole ) in the United States 12/16/2024 6:15:00 AM
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® ( ceftobiprole ) in the United States - Innoviva ( NASDAQ:INVA ) 12/16/2024 6:15:00 AM
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer - Xenon Pharmaceuticals ( NASDAQ:XENE ) 8/12/2024 12:30:00 PM
Innoviva ( NASDAQ:INVA ) Upgraded to Strong-Buy by StockNews.com 7/17/2024 12:35:00 AM
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs - Innoviva ( NASDAQ:INVA ) 6/18/2024 5:44:00 PM

Financial Details for INVA

Company Overview

Ticker INVA
Company Name Innoviva Inc
Country USA
Description Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 18.97
Price 4 Years Ago 17.25
Last Day Price Updated 5/27/2025 3:11:59 PM EST
Last Day Volume 808,594
Average Daily Volume 661,788
52-Week High 21.28
52-Week Low 15.20
Last Price to 52 Week Low 24.80%

Valuation Measures

Trailing PE N/A
Industry PE 21.34
Sector PE 39.72
5-Year Average PE 17.29
Free Cash Flow Ratio 3.73
Industry Free Cash Flow Ratio 16.88
Sector Free Cash Flow Ratio 31.24
Current Ratio Most Recent Quarter 2.48
Total Cash Per Share 5.08
Book Value Per Share Most Recent Quarter 10.31
Price to Book Ratio 1.84
Industry Price to Book Ratio 34.13
Sector Price to Book Ratio 29.89
Price to Sales Ratio Twelve Trailing Months 3.22
Industry Price to Sales Ratio Twelve Trailing Months 146.12
Sector Price to Sales Ratio Twelve Trailing Months 39.44
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 62,775,000
Market Capitalization 1,190,841,750
Institutional Ownership N/A

Dividends

Ex-Dividend Date 9/8/2015
Previous Dividend Amount 0.0000
Current Dividend Amount 0.2500
Total Years Dividend Increasing 2
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 1.41
Forward Annual Dividend Yield 7.93%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 33.33%
3-Year Dividend Growth Rate Percentage 41.42%
5-Year Dividend Growth Rate Percentage 41.42%
All-Time Dividend Growth Rate Percentage 50.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -63.00%
Annual Earnings Growth -86.98%
Reported EPS 12 Trailing Months -0.95
Reported EPS Past Year -0.74
Reported EPS Prior Year 0.19
Net Income Twelve Trailing Months -59,724,000
Net Income Past Year 23,392,000
Net Income Prior Year 179,722,000
Quarterly Revenue Growth YOY 14.40%
5-Year Revenue Growth 6.57%
Operating Margin Twelve Trailing Months 47.00%

Balance Sheet

Total Cash Most Recent Quarter 319,090,000
Total Cash Past Year 304,964,000
Total Cash Prior Year 193,513,000
Net Cash Position Most Recent Quarter 62,420,000
Net Cash Position Past Year 48,648,000
Long Term Debt Past Year 256,316,000
Long Term Debt Prior Year 446,234,000
Total Debt Most Recent Quarter 256,670,000
Equity to Debt Ratio Past Year 0.73
Equity to Debt Ratio Most Recent Quarter 0.72
Total Stockholder Equity Past Year 691,159,000
Total Stockholder Equity Prior Year 674,955,000
Total Stockholder Equity Most Recent Quarter 646,905,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 195,990,000
Free Cash Flow Per Share Twelve Trailing Months 3.12
Free Cash Flow Past Year 188,420,000
Free Cash Flow Prior Year 140,653,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.16
MACD Signal 0.16
20-Day Bollinger Lower Band 17.12
20-Day Bollinger Middle Band 18.14
20-Day Bollinger Upper Band 19.16
Beta 0.36
RSI 57.83
50-Day SMA 18.28
150-Day SMA 15.19
200-Day SMA 15.58

System

Modified 5/27/2025 2:41:08 AM EST